Author:
Junlén H R,Peterson S,Kimby E,Lockmer S,Lindén O,Nilsson-Ehle H,Erlanson M,Hagberg H,Rådlund A,Hagberg O,Wahlin B E
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference45 articles.
1. Harris NL, Swerdlow SH, Jaffe ES, Ott G, Nathwani D . Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008, pp 220–226.
2. Hiddemann W, Cheson BD . How we manage follicular lymphoma. Leukemia 2014; 28: 1388–1395.
3. Bezombes C, Fournie JJ, Laurent G . Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives. Mol Cancer Res 2011; 9: 1435–1442.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
5. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423.
Cited by
101 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献